tiprankstipranks

MediWound to host virtual KOL event to discuss EscharEx Phase III VALUE study

MediWound (MDWD) will host a virtual Key Opinion Leader event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcers and EscharEx’s commercial opportunity. Discussion Topics Include: Compelling results to date from Phase II studies of EscharEx The upcoming Phase III VALUE study of EscharEx in VLUs The substantial unmet need and current treatment landscape for VLUs and diabetic foot ulcers EscharEx’s competitive advantages and unique commercial potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue